REVVITY, INC. RVTY

The strongest current fact in RVTY is the official earnings rail. Revvity announced first-quarter 2026 financial results in an SEC EDGAR 8-K on 2026-05-05, then filed its 10-Q on 2026-05-12. The latest parsed 10-Q reports revenue from contract with customer, excluding assessed tax, of $711.1M for the period ending 2026-04-05, operating income of $75.9M, net income attributable to parent of $40.7M and diluted EPS of $0.36.

The supplied evidence shows an operating products business, not a ticker with a slogan attached. Revvity reports product revenue, a Diagnostics segment, a Reproductive Health business, research and development expense, inventory and payments to acquire property, plant and equipment. That matters because this equity story turns on product demand, testing workflows, currency translation, cash generation and the cost of keeping the product base current.

The financial core is specific. The 10-Q for the period ending 2026-04-05 shows assets of $12.00B, liabilities of $4.81B and stockholders' equity attributable to parent of $7.18B. Cash and cash equivalents were $860.3M. Net cash provided by operating activities was $115.2M, while payments to acquire property, plant and equipment were $19.8M. The same filing lists research and development expense of $57.9M, inventory of $387.5M, an increase in inventories of $12.8M and diluted weighted average shares outstanding of 111.9M.

The product and segment rail gives the file its pulse. Product revenue was listed as $581.458M against $562.680M. Diagnostics segment revenue was $349.3M for the three months ended April 5, 2026, compared with $324.4M for the three months ended March 30, 2025, an increase of $24.9M, or 8%. The company attributed that increase to Reproductive Health and favourable changes in foreign exchange rates, including a $20.6M increase in Reproductive Health revenue.

The public developments are filing-led. The source list includes the 8-K on 2026-05-05, the 10-Q on 2026-05-12, two Form 4 filings on 2026-05-11, a Schedule 13G/A on 2026-05-15, an SD filing on 2026-06-01 and a Form 4 on 2026-06-17, all through SEC EDGAR. Those are real public events, but the supplied rail does not parse the Form 4 transaction amounts, the amended 13G ownership details or the SD substance, so they should be treated as source markers rather than story fillers.

No chart route, TradingView source, price, volume or technical level appears in the supplied pack. This report therefore uses the market mechanism that can be proved: filings, earnings facts, segment movement, product revenue, cash, inventory, R&D and balance-sheet capacity. The next stronger version of the file would need parsed ownership detail from the Form 4 and Schedule 13G/A filings, plus any later operating data after the quarter ended 2026-04-05.